CD8A and myeloid sarcoma: Although a definite functional link between MS pathology and the observed differences in type I IFN response, in particular in B cells remains to be established, our data challenge the prevailing view that the protective influence of HLA-A*02 and B*44 are mechanistically related to preferences in peptide binding [61], either in the defence against a pathogen associated with MS such as EBV [62], or presentation of peptides related to CD8+ T cells involved in suppressing disease [39].